Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Vaxcyte, Inc.
  6. News
  7. Summary
    PCVX   US92243G1085

VAXCYTE, INC.

(PCVX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Vaxcyte Investor Presentation November 2021

11/10/2021 | 05:37pm EST

Corporate Presentation

November 10, 2021

Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include but are not limited to, statements related to the benefits of Vaxcyte's vaccine candidates; the process and timing of anticipated future development of Vaxcyte's vaccine candidates, including the timing and submission of an IND application for VAX-24 and the initiation of the VAX-24 Phase 1/2 clinical proof-of-concept study thereafter; the timing and availability of topline data for VAX-24; the ability to complete the manufacturing of the GMP drug product; the successful testing and release of the final drug product for VAX-24 and documentation of stability; the achievement of future funding milestones; the use and availability of funds from CARB-X; the nomination of a final vaccine candidate for VAX-PG; the market opportunity for our vaccines; our expectations regarding the potential benefits, spectrum coverage and immunogenicity of our vaccine candidates; the timing of the initiation, progress and expected results of our preclinical studies, clinical trials and research and development plans; and other statements that are not historical fact. The words "anticipate," "believe," "continue," "could," "designed," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

These forward-looking statements are based on Vaxcyte's current expectations and actual results and timing of events could differ materially from those anticipated in such forward-looking statements as a result of risks and uncertainties, including, without limitation, risks related to Vaxcyte's product development programs, including development timelines, success and timing of chemistry, manufacturing and controls and related manufacturing activities; Vaxcyte's reliance on third-party manufacturers; potential delays or inability to obtain and maintain required regulatory approvals for its vaccine candidates; the risks and uncertainties inherent with preclinical and clinical development processes; the success, cost and timing of all development activities and clinical trials; sufficiency of cash and other funding to support Vaxcyte's development programs and other operating expenses; and the ongoing COVID-19 pandemic, which could materially and adversely affect Vaxcyte's business and operations. These and other risks are described more fully in Vaxcyte's filings with the Securities and Exchange Commission (SEC), including its Quarterly Report on Form 10-Q filed with the SEC on November 10, 2021 or in other documents Vaxcyte subsequently files with or furnishes to the SEC. Vaxcyte undertakes no duty or obligation to update any forward-

2 looking statements contained in this release as a result of new information, future events or changes in its expectations.

Vaxcyte Mission Statement

Seeking to improve global health by developing

superior & novel vaccines designed to prevent or treat

some of the most common & deadly infectious

diseases worldwide.

3

Key Corporate Highlights

Next-Generation Vaccine Company - Led by Pneumococcal Conjugate Vaccine (PCV) Franchise

Large Market

Opportunity for PCV

Franchise

Cell-Free

Protein Synthesis

Platform

Disciplined

Robust

Aligned

Target

Development

Critical

Selection

Pipeline

Resources

  • Scalable PCV platform enabling broader-spectrumPCVs: VAX-24& VAX-XP
  • Lead candidate: VAX-24
    • 24-valentPCV with potential to replace SOC
    • Anticipated IND filing in Q1:22(1)
    • Anticipated Phase 1/2 data readout in late '22- early '23(1)

4 (1) Guidance provided as of November 10, 2021.

  • Leverages site- specific conjugation
  • Permits production of
    "tough-to-make" antigens
  • Demonstrated speed, flexibility, and scalability

• Targets well-defined

• Platform unlocks large

>$7B market segment

market opportunities:

• Honors well-

- VAX-A1: Novel Group A

understood PCV MOA

Strep conjugate vaccine

• Leverages established

- VAX-PG: Novel

surrogate immune

periodontitis therapeutic

endpoints and clinical

vaccine

pathways

  • Strategic alignment with Lonza (manufacturing)
  • Seasoned management team, directors and advisors
  • Cash, cash equivalents and investments of $318.3M at 9/30/21

Experienced Team, Board of Directors, and Scientific Advisors

Outstanding Track Record in Vaccines and Biopharma

Management Team

Board of Directors

Grant Pickering, MBA

Jim Wassil, MS, MBA

Andrew Guggenhime,

Carlos Paya, MD, PhD

Annie Drapeau

Halley Gilbert

CEO & Co-founder

COO

MBA

Chair

President & CFO

Peter Hirth, PhD

Michael Kamarck, PhD

Teri Loxam

Heath Lukatch, PhD

Kurt von Emster

Grant Pickering

Jeff Fairman, PhD

Paul Sauer, MBA

Harp Dhaliwal, MBA

Scientific Advisory Board

VP Research &

SVP PD & Manufacturing

SVP Commercial

Co-founder

Manufacturing & Supply

Jeff Almond, PhD

Tony Ford-Hutchinson,

Emmanuel Hanon,

Chain

PhD

PhD

Bill Hausdorff, PhD

Tom Monath, MD

Emmanuel Walter,

MD, MPH

5

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Vaxcyte Inc. published this content on 10 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 10 November 2021 22:33:07 UTC.


ę Publicnow 2021
All news about VAXCYTE, INC.
01/13VAXCYTE, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
01/13AFTER HOURS WATCH LIST SCORECARD : Kbh, pcvx, estc
MT
01/13Health Care Stocks Losing More Ground as Biotechs Sputter in Late Trade
MT
01/13Health Care Stocks Fading Thursday as Biotechs Stumble
MT
01/13Health Care Stocks Mixed Pre-Bell Thursday
MT
01/13Vaxcyte Prices Offering of Common Shares, Warrants; Expects $100 Million Gross Proceeds
MT
01/13Vaxcyte Announces Pricing of $100 Million Public Offering
GL
01/13Vaxcyte Announces Pricing of $100 Million Public Offering
GL
01/12MT NEWSWIRES AFTER HOURS WATCH LIST : Kbh, pcvx, estc
MT
01/12Vaxcyte Launches Public Offering of Shares, Warrants; Stock Plunge After-Hours
MT
More news
Financials (USD)
Sales 2021 - - -
Net income 2021 -100 M - -
Net Debt 2021 - - -
P/E ratio 2021 -9,34x
Yield 2021 -
Capitalization 982 M 982 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 982x
Nbr of Employees 58
Free-Float 84,9%
Chart VAXCYTE, INC.
Duration : Period :
Vaxcyte, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VAXCYTE, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 17,63 $
Average target price 50,50 $
Spread / Average Target 186%
EPS Revisions
Managers and Directors
Grant E. Pickering Chief Executive Officer & Director
Andrew L. Guggenhime President & Chief Financial Officer
Carlos V. Paya Chairman
Romulo Colindres Chief Medical Officer
Jim Wassil Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
VAXCYTE, INC.-25.89%975
GILEAD SCIENCES, INC.-4.88%86 640
REGENERON PHARMACEUTICALS-2.12%64 627
VERTEX PHARMACEUTICALS5.12%58 692
WUXI APPTEC CO., LTD.-6.39%51 406
BIONTECH SE-37.29%39 044